HER2-positive metastatic breast cancer: standards and new developments

被引：0

作者：

Fehm, Tanja ^{[1
]}

Mueller, Volkmar ^{[2
]}

机构：

[1] Univ Tumorzentrum Dusseldorf, Univ Frauenklin Dusseldorf, Dusseldorf, Germany

[2] Univ Klinikum Hamburg Eppendorf, Klin & Poliklin Gynakol, Martinistr 52, D-20246 Hamburg, Germany

来源：

ONKOLOGE | 2020年 / 26卷 / 06期

关键词：

Trastuzumab; Receptor ErbB-2; Molecular targeted therapy; Antibodies; monoclonal; humanized; Protein-tyrosine kinases; TRASTUZUMAB EMTANSINE; MONOCLONAL-ANTIBODY; HER2; COMBINATION;

D O I：

10.1007/s00761-020-00724-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With the development of the monoclonal antibody trastuzumab against HER2, a significant breakthrough was achieved in the treatment of metastatic HER2-positive breast cancer. In the years that followed, dual blockade with the antibodies trastuzumab and pertuzumab in combination with taxane-containing chemotherapy resulted in a further significant improvement in both the metastatic and adjuvant treatment situation. The relevant literature was evaluated. T-DM1, which is an antibody-drug conjugate comprising trastuzumab and mertansine, has further increased survival in the metastatic situation after trastuzumab compared to the former second-line treatment standard capecitabine/lapatinib. New drug developments include tyrosine kinase inhibitors such as neratinib and tucatenib as well as innovative antibody-drug conjugates including trastuzumab-deruxtecane. As various new substances are currently being evaluated, patients should be included in treatment studies whenever possible.

引用

页码：518 / 523

页数：6

共 28 条

[1] Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10 [J].

Abraham, Jame ;

Montero, Albert J. ;

Jankowitz, Rachel C. ;

Salkeni, Mohamad Adham ;

Beumer, Jan H. ;

Kiesel, Brian F. ;

Piette, Fanny ;

Adamson, Laura M. ;

Nagy, Rebecca J. ;

Lanman, Richard B. ;

Sperinde, Jeff ;

Huang, Weidong ;

Allegra, Carmen J. ;

Srinivasan, Ashok ;

Wang, Ying ;

Pogue-Geile, Katherine L. ;

Lucas, Peter C. ;

Jacobs, Samuel A. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (29) :2601-+

[2] Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) [J].

Bachelot, T. ;

Ciruelos, E. ;

Schneeweiss, A. ;

Puglisi, F. ;

Peretz-Yablonski, T. ;

Bondarenko, I. ;

Paluch-Shimon, S. ;

Wardley, A. ;

Merot, J. -L. ;

du Toit, Y. ;

Easton, V. ;

Lindegger, N. ;

Miles, D. ;

Bouzid, Kamel ;

Campone, Mario ;

Coudert, Bruno ;

Nowecki, Zbigniew ;

Errihani, Hassan ;

Dalenc, Florence ;

Ferreira, Ana ;

Mano, Max ;

Ricci, Francesco ;

Kalofonos, Haralabos ;

Andreetta, Claudia ;

Montemurro, Filippo ;

Barrett, Sophie ;

Zhang, Qingyuan ;

Mavroudis, Dimitris ;

Matus, Juan ;

Beato, Carlos ;

Hu, Xichun ;

Gaafar, Rabab ;

Azeem, Hamdy Abdel ;

Perrin, Christophe ;

Ettl, Johannes ;

Lang, Istvan ;

Verma, Sunil ;

Li, Huiping ;

Brain, Etienne ;

Hoffmann, Oliver ;

Cariello, Anna ;

Tondini, Carlo ;

Altwegeiri, Taher ;

Loman, Niklas ;

Lux, Michael ;

Frassoldati, Antonio ;

Aziz, Zeba ;

Salas, Fernando ;

Streb, Joanna ;

Wronski, Andrzej .

ANNALS OF ONCOLOGY, 2019, 30 (05) :766-773

[3] First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors [J].

Bang, Y. J. ;

Giaccone, G. ;

Im, S. A. ;

Oh, D. Y. ;

Bauer, T. M. ;

Nordstrom, J. L. ;

Li, H. ;

Chichili, G. R. ;

Moore, P. A. ;

Hong, S. ;

Stewart, S. J. ;

Baughman, J. E. ;

Lechleider, R. J. ;

Burris, H. A. .

ANNALS OF ONCOLOGY, 2017, 28 (04) :855-861

[4] Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study [J].

Blackwell, Kimberly L. ;

Burstein, Harold J. ;

Storniolo, Anna Maria ;

Rugo, Hope S. ;

Sledge, George ;

Aktan, Gursel ;

Ellis, Catherine ;

Florance, Allison ;

Vukelja, Svetislava ;

Bischoff, Joachim ;

Baselga, Jose ;

O'Shaughnessy, Joyce .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2585-2592

[5] Tucatinib Combined With Ado-Trastuzumab Emtansine in Advanced ERBB2/HER2-PositiveMetastatic Breast Cancer A Phase 1b Clinical Trial [J].

Borges, Virginia F. ;

Ferrario, Cristiano ;

Aucoin, Nathalie ;

Falkson, Carla ;

Khan, Qamar ;

Krop, Ian ;

Welch, Stephen ;

Conlin, Alison ;

Chaves, Jorge ;

Bedard, Philippe L. ;

Chamberlain, Marc ;

Gray, Todd ;

Vo, Alex ;

Hamilton, Erika .

JAMA ONCOLOGY, 2018, 4 (09) :1214-1220

[6]

FREEDMAN RA, 2019, CLIN BREAST CANC

[7] Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial [J].

Huober, J. ;

Fasching, P. A. ;

Barsoum, M. ;

Petruzelka, L. ;

Wallwiener, D. ;

Thomssen, C. ;

Reimer, T. ;

Paepke, S. ;

Azim, H. A. ;

Ragosch, V. ;

Kubista, E. ;

Baumgaertner, A. K. ;

Beckmann, M. W. ;

May, C. ;

Nimmrich, I. ;

Harbeck, N. .

BREAST, 2012, 21 (01) :27-33

[8] Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer [J].

Johnston, Stephen ;

Pippen, John, Jr. ;

Pivot, Xavier ;

Lichinitser, Mikhail ;

Sadeghi, Saeed ;

Dieras, Veronique ;

Gomez, Henry Leonidas ;

Romieu, Gilles ;

Manikhas, Alexey ;

Kennedy, M. John ;

Press, Michael F. ;

Maltzman, Julie ;

Florance, Allison ;

O'Rourke, Lisa ;

Oliva, Cristina ;

Stein, Steven ;

Pegram, Mark .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :5538-5546

[9] Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study [J].

Kaufman, Bella ;

Mackey, John R. ;

Clemens, Michael R. ;

Bapsy, Poonamalle P. ;

Vaid, Ashok ;

Wardley, Andrew ;

Tjulandin, Sergei ;

Jahn, Michaela ;

Lehle, Michaela ;

Feyereislova, Andrea ;

Revil, Cedric ;

Jones, Alison .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :5529-5537

[10] Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial [J].

Krop, Ian E. ;

Kim, Sung-Bae ;

Gonzalez Martin, Antonio ;

LoRusso, Patricia M. ;

Ferrero, Jean-Marc ;

Badovinac-Crnjevic, Tanja ;

Hoersch, Silke ;

Smitt, Melanie ;

Wildiers, Hans .

LANCET ONCOLOGY, 2017, 18 (06) :743-754

← 1 2 3 →